A 87049

Drug Profile

A 87049

Latest Information Update: 22 Jan 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abbott Laboratories
  • Class Amides; Antihyperlipidaemics; Dicarboxylic acids
  • Mechanism of Action Squalene synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Hypercholesterolaemia

Most Recent Events

  • 02 Jan 2013 Abbott separates its pharmaceuticals business to a new company called AbbVie
  • 24 Sep 1999 A study has been added to the Hyperlipidaemia pharmacodynamics section
  • 17 Jun 1996 Preclinical development for Hypercholesterolaemia in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top